<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hemorrhagic transformation (HT) is a major factor limiting the use of tissue plasminogen activator (tPA) for <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>This study examined the role of <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> (DFX) in brain injury and HT in a rat model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Rats received an injection of 50% <z:chebi fb="105" ids="17234">glucose</z:chebi> (6 mL/kg, i.p.) 15 min before undergoing transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO; 2 h occlusion) with reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Rats were treated with DFX (100 mg/ kg, i.m.) or vehicle immediately after tMCAO </plain></SENT>
<SENT sid="4" pm="."><plain>Rats were killed at 4, 8 and 24 h later and used for <z:hpo ids='HP_0002181'>brain edema</z:hpo>, blood-brain barrier permeability, <z:mp ids='MP_0001914'>hemorrhage</z:mp> volume, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measurements </plain></SENT>
<SENT sid="5" pm="."><plain>Mortality rate was also evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>DFX treatment reduced mortality at 24 h (4% vs. 24% in the vehicle-treated group, p&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>DFX also reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (85.1+/-56.3 vs. 164.3+/-93.4 mm(3) in vehicle, p&lt;0.05) and swelling in the basal ganglia (p&lt;0.05) 24 h after tMCAO </plain></SENT>
<SENT sid="8" pm="."><plain>The total <z:mp ids='MP_0001914'>hemorrhage</z:mp> volume in the ipsilateral hemisphere at 8 h post tMCAO was less in DFX-treated animals (p&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>However, blood-brain barrier permeability was same in DFX- and vehicle-treated groups </plain></SENT>
<SENT sid="10" pm="."><plain>DFX attenuates <z:hpo ids='HP_0011420'>death</z:hpo> rate, hemorrhagic transformation, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> in a rat transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> model, suggesting that DFX could be potential treatment to reduce the hemorrhagic transformation for <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>